Some pharmacogenetic tests may provide ancillary disease risk information. To evaluate evidence and assess the social and policy implications of ancillary disease risk information associated with candidate pharmacogenetic variants, We conducted a literature search and abstract review of disease susceptibility studies for each of 42 gene variants potentially associated with drug response. Twenty-two variants (53%) had suggested association with disease risk in at least two studies, and sixteen (38%) were for diseases other than the pharmacogenetic indication. Seven variants (16%) were associated with risk for at least two different diseases. Pharmacogenetic tests have the potential to provide ancillary disease risk information, and this potential should be considered as pharmacogenetic tests are brought into clinical use. Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information.
Introduction
Pharmacogenetics is the study of the contribution of genes and gene variants to inter-individual variation in drug response. 1 Although the study of genetic determinants of drug response began more than 50 years ago, 2 the completion of the Human Genome Project has made it possible to envision the common use of pharmacogenetic testing to individualize drug therapy. Pharmacogenetics may become one of the first widespread clinical uses of genetic information in health care.
Ancillary risk information can be defined as information on an individual's disease risk provided by a genetic test that is unintended and outside the original use of the test, and can potentially arise in research or clinical contexts. It has been suggested that ethical concerns for pharmacogenetic testing may be less significant compared to other genetic tests because of its more specific purpose of improving drug treatment. 3, 4 Perhaps ancillary disease risk information has not been described as a potentially important issue in pharmacogenetic testing in part because of the types of variants that have shown promise. Genes that code for drug metabolizing enzymes -currently the most common clinical application of pharmacogenetics -generally have not been implicated in disease risk, so ethical analysis of pharmacogenetics has focused on access and distribution of beneficial technologies and the social and ethical implications of race-or ethnicity-based prediction of safety or benefit. 3, 5 Furthermore, risk information provided by a pharmacogenetic test would often be for the same disease as the drug treatment, potentially mitigating the implications of ancillary information. A predominant paradigm that pharmacogenetic testing is unlikely to provide significant disease risk information has therefore been suggested. [6] [7] [8] However, while the existence of ancillary risk information in the context of pharmacogenetic testing is conceptually very real, neither the potential scope of the issue nor consideration of the ethical and social implications of such information has been well studied. Therefore, our objective was to conduct a literature-based inquiry to estimate the potential scope and variation of ancillary disease risk information and to discuss the social and policy implications of this type of information.
Results
We reviewed the abstracts of 555 studies that met our inclusion and exclusion criteria. For consistent interpretation, we have presented the results in terms of variants and their potential associations with disease risk. Twenty-two (53%) of the 42 variants we studied were reported to have a significant association with disease risk in at least two published studies. The risk in sixteen (38%) of these variants was for diseases other than the pharmacogenetic indication (Table 1) . Seven variants (17%) were associated with risk for at least two different diseases. Thirty-three variants (79%) were reported to be associated with risk of a disease in only one study. We found studies suggesting conflicting results for risk of at least one disease for 22 variants (54%). We found only reports of negative results for a disease for 28 variants (67%).
We describe below several examples to highlight relevant characteristics of potential ancillary disease risk information.
Two studies versus only one study suggesting association with disease risk Several variants have been well-studied; in addition to established associations, these variants often also have many reported associations with disease risk that have not been replicated. For example, Goldstein et al. report that ACE (In-del variant) may predict decreased proteinuria in response to ACE inhibitors for renal disease; according to our review, this variant may also be associated with risk for Alzheimer disease. 9 However, this variant also has 21 'one positive study' results, suggesting unconfirmed but potential associated risk for 21 other diseases. Also, in the TNF gene variant G308A, the drug response is immunosuppressive therapy for aplastic anemia and sensitivity to the seizure medication carbamazepine. We found studies associating this variant with risk for rheumatoid arthritis, tuberculosis, celiac disease, and ulcerative colitis. [10] [11] [12] [13] Mental or behavioral disorders Several variants were associated in at least one study with diseases that are associated with mental or behavioral disorders. The A1/A2 variant of the DRD2 gene may predict greater response to antipsychotics, and at least two studies suggest an association with risk for alcoholism.
14,15 GNB3 gene variants (C825T) may predict response to antidepressants, and is also associated with risk for obesity and type 2 diabetes. The promoter VNTR variant of the SLC6A3 gene may predict responders to the ADHD medication methylphenidate, and may also predict cigarette smoking behavior. 16, 17 Severity or treatability of disease The E4 variant of the APOE gene is well known for risk of Alzheimer disease; there is also potential drug response use predicting non-responders to statins. 18,19. Similarly, the C667T variant of the MTHFR gene may predict toxicity from methotrexate therapy, and MTHFR gene variants may also be associated with increased risk for several types of cancer, migraine, neural tube defects, and stroke. [20] [21] [22] [23] Several of the variants may provide ancillary risk information about various types of cancer (XRCC1, GSTM1, GSTP1, MTHFR, CYP2C9), many amenable to early detection and surveillance interventions that improve health outcomes. 20, [24] [25] [26] Based on these findings, we determined that the policy implications of ancillary information would be highly dependent on the characteristics of the individual tests: the strength of the risk estimate, the severity and potential for stigma of the associated disease, and the treatability of the disease. Tests whose associated disease risk are of high risk, are more severe or life-threatening or stigmatizing, and These categories do not include a consideration of the number or proportion of negative studies.
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that are untreatable will be more likely to have important social, ethical, and policy implications.
Discussion
We conducted a review for evidence of disease risk associated with pharmacogenetic variants. Our results confirm the estimate of Goldstein and colleagues that at least 23 of 42 pharmacogenetic variants provide ancillary disease risk information and further characterize the nature of ancillary risk information. 6 Our estimates provide a starting point for describing the potential scope and nature of ancillary risk information and provide a window into the dynamic state of genetic susceptibility research and the challenges in validating genetic associations. Although detailed assessment of study quality was outside the scope of this review, there appeared to be a wide range of quality in the studies we identified, with at least some studies limited by methodological weaknesses such as small sample sizes and potential population stratification. However, it is possible that overall these estimates of relationship between pharmacogenetic variants and disease variants may underestimate the true relationship since much of pharmacogenetic research is on pharmacokinetics. As more research focuses on pharmacodynamics, the scope for commonality between disease and pharmacogenetic variation expands.
Our results highlight that the strength of risk is an important consideration, and the range of risk estimates we observed indicates a need for development of consensus on level of risk considered clinically significant. For example, a risk of 1.3 might be statistically significant, but not significant enough to warrant disclosure. When risk is clinically significant, the nature of the condition and its treatability become important considerations. Arguably, clinicians have a duty to disclose risks for diseases that are both severe and treatable in order to provide opportunities for early or preventive treatment. Patients also have a right to know if a test will reveal risks for untreatable disease or potentially stigmatizing condition such as mental illness. Thus, in addition to threshold of clinical significance, there is need for consensus development on appropriate informed consent procedures and follow-up.
An interesting finding of our study was the large proportion of variants (79%) for which we found only one study suggesting a particular disease association; some were reported to be associated with risk for up to 20 diseases based on only one study assessing each association. These findings may be subject to publication bias -the tendency for positive studies to be published more frequently than negative ones. It is also possible that some variants are still under study or that validation studies have not been attempted. Regardless, our finding indicates the need for periodic review to update the evidence for gene-drug and gene-disease associations and determine the proportion of associations that are subsequently confirmed.
Our data suggest that the ancillary risk information associated with specific variants may change as more studies are completed and associations disproved or verified. For many variants the clinical utility of pharmacogenetic test use remains uncertain, regardless of ancillary information. Arguably only a few genetic variants may provide clinical utility, such as TPMT genotype and adverse response to 6-MP chemotherapy, and CYP29 genotype and warfarin dosing. The validity of several well-cited examples of pharmacogenetic associations -CETP variants and response to statins, alpha-adducin and response to diuretics, and ACE variants and response to ACE inhibitors -have recently been called into question. [27] [28] [29] [30] [31] [32] In addition, well-known and wellstudied polymorphisms such as these may be more likely to be studied for their associated pharmacogenetic effects, which may introduce bias when conducting inquiries such as ours.
Ancillary risk information represents an unintended consequence of tests performed to improve health care by predicting drug response, adverse events, and dosage requirements. 1 Our data indicate that some variants very likely will provide ancillary disease risk information. The benefit of treating disease using pharmacogenetics may often outweigh any potential harm posed by ancillary risk information, such as in cases where genetic information provides highly predictive information on drug response or adverse effects. In other cases, ancillary information might itself provide benefit by identifying a risk that could be reduced by early intervention. However, in some instances the potential harm of ancillary information may outweigh the benefit of the test, and evaluation of these tests for clinical use needs to consider this potential. Ancillary risk information may warrant the most careful scrutiny when there are compelling data for both pharmacogenetic benefit and disease risk; especially when the disease risk is high and the disease is severe and untreatable or stigmatizing, such as risk for Alzheimer disease, alcoholism or mental illness. Cases where significant disease risk associations are identified after patients have received pharmacogenetic testing will add a further challenge.
Unless recognized proactively and included in practice guideline development and other policy-making activities, the potential harm of ancillary risk information might not be considered. Policy makers will need to consider when and how ancillary information should be provided to patients, whether formal informed consent procedures are needed, and how risks and benefits of ancillary risk information should be weighed. Many scholars have argued against an exceptionalist approach to genetic information. [33] [34] [35] While genetic information is not inherently exceptional compared to phenotypic risk information of the same magnitude, genetic tests may raise the issue of ancillary information more often because of the pleiotropic effects of many variants.
This study has limitations. We did not evaluate all possible pharmacogenetic variants, and other drug response associations may have emerged since the original list was published (4) . For disease associations, we used the inclusion criteria of at least two positive studies, with no explicit consideration of the number of 'negative' studies; this definition may be lenient. For example, Hirschhorn et al. used the criteria of positive results in at least 75% of published studies to define a valid association; of 166 putative associations between disease risk and genotype, only six variants met this criteria. 36 As such, the pharmacogenetic associations we studied (4) and the disease risk associations we identified likely include some 'false positives.' Our analysis was intended to provide an overview of ancillary disease risk information, and thus did not examine in detail the clinical nuances of any one variant or its accompanying disease risk, and having only reviewed abstracts we cannot comment on the quality of the studies. Disease-specific or variant-specific inquiries into potential ancillary risk information should be pursued in more detail in future work.
Nevertheless, our data indicate that a substantial proportion of pharmacogenetic tests may provide ancillary disease risk information. Evaluating the validity of both pharmacogenetics and disease risk associations is challenging, but the potential for ancillary disease risk information should be considered. We anticipate that the implications of ancillary risk information will vary widely by each test and its abilities to detect disease risk of varying severity, stigma, and treatability. Researchers and policy makers should consider ancillary information in pharmacogenetic research and policies on the use of pharmacogenetic tests in practice. It may sometimes provide an additional benefit to a patient; at other times it may represent unwelcome information that must be considered in relation to the benefit of the pharmacogenetic test.
Materials and methods
We conducted a literature search and abstract review of gene variant -disease risk association studies relevant to pharmacogenetics. We chose a list of previously published by Goldstein et al. 6 of 42 genetic variants that have been associated with drug response in at least two published studies as our source list of pharmacogenetic variants (Table 2) . Given the difficulty of determining the validity of genetic associations these associations cannot be considered definitively validated, but the list provides a representative sample of genetic variants being studied for pharmacogenetic implications. Using PubMed, we searched for human English-language studies published since 2000 using the search terms '[variant name] gene' AND 'risk or susceptibility.' To define potential variant-disease associations, we used the same criteria as Goldstein et al.: the publication of at least two association studies of the genetic variant of interest and disease risk. We defined a positive finding as an association with statistical significance at the alpha 0.05 level or confidence intervals for odds or risk ratios that did not include 1.0. We collected the following information from the abstracts: the variant under study, the disease association being tested; whether the finding was a positive (indicating a variant-disease association) or negative (not indicating a variant-disease association); and whether the noted association was for the same disease as the potential pharmacogenetic use. In compiling our data we noted, for each variant: diseases for which there was an association in one study only; conflicting results (both association and no association suggested in different studies); and diseases for which no association was found. We excluded review articles and abstracts that did not clearly state the variant under study. After collecting these data we categorized the results by potential social, ethical, or policy implications to begin to understand the scope and implications of ancillary risk information as they apply to future research and policy.
